New Science

Use of Kenvue’s Nicorette QuickMist nicotine replacement therapy device resulted in “statistically significant reductions in urges to vape as soon as 30 seconds and up to two hours after dosing compared with placebo,” according to a recently published study funded by the firm.

Philip Morris described a scenario of being essentially blacklisted by the health care sector and its CDMO partners as it threw in the towel on its £1.1bn acquisition of UK inhalation specialist Vectura. It agreed to offload the firm at a fraction of the initial cost.

Philip Morris described a scenario of being essentially blacklisted by the health care sector and its CDMO partners as it threw in the towel on its £1.1bn acquisition of UK inhalation specialist Vectura. It agreed to offload the firm at a fraction of the initial cost.

Data at WCLC showed why the TROP2-targeting ADC datopotamab deruxtecan is most effective in non-squamous NSCLC in second or later lines as presented in overall survival data at the meeting.

In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry. 

King’s College London has released a freely available ‘Human Gut Microbiome Atlas’ to help researchers better understand how microorganisms in the gut impact disease. 

A recently-published study funded by the UK National Institute for Health and Care Research finds that use of OTC nasal sprays reduces overall respiratory illness duration by about a fifth. Applied at a population level, self-care could therefore save billions in healthcare and human capital costs, as industry has pointed out elsewhere, as well as redirecting people away from antibiotic treatments that are still widely misprescribed, contributing to the fight against antimicrobial resistance. 

Biopharmaceutical venture capital fundraising is on the rise in 2024. In late June, Formation Bio secured a mega financing, raising $372m via a series D round led by a16z and Sanofi. 

Consumer health companies need to meet consumers where they are in their life-stage journeys, providing healthy aging solutions like dietary supplements that have clearly communicated and science-backed benefits, argued panelists at a recent IQVIA Consumer Health webinar. This is particularly the case for women, who are underserved and want natural support for changes like the menopause, said Haleon's Sheryl Tan. 

Grey Wolf Therapeutics has secured $99m via an expanded series B financing to advance its antigen modulation approach in cancer and to further explore its use in autoimmune disease indications.